- Home
- CASI vs IMMX Comparison
CASI vs IMMX Comparison
Compare CASI & IMMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CASI
- IMMX
- Stock Information
- Founded
- CASI 1991
- IMMX 2014
- Country
- CASI China
- IMMX United States
- Employees
- CASI N/A
- IMMX N/A
- Industry
- CASI Biotechnology: Pharmaceutical Preparations
- IMMX Medicinal Chemicals and Botanical Products
- Sector
- CASI Health Care
- IMMX Health Care
- Exchange
- CASI Nasdaq
- IMMX Nasdaq
- Market Cap
- CASI 35.0M
- IMMX 44.8M
- IPO Year
- CASI 1996
- IMMX 2021
- Fundamental
- Price
- CASI $2.21
- IMMX $1.64
- Analyst Decision
- CASI Strong Buy
- IMMX Strong Buy
- Analyst Count
- CASI 1
- IMMX 1
- Target Price
- CASI $6.00
- IMMX $7.00
- AVG Volume (30 Days)
- CASI 8.1K
- IMMX 73.5K
- Earning Date
- CASI 03-27-2025
- IMMX 03-28-2025
- Dividend Yield
- CASI N/A
- IMMX N/A
- EPS Growth
- CASI N/A
- IMMX N/A
- EPS
- CASI N/A
- IMMX N/A
- Revenue
- CASI $22,055,000.00
- IMMX N/A
- Revenue This Year
- CASI N/A
- IMMX N/A
- Revenue Next Year
- CASI $134.79
- IMMX $600.00
- P/E Ratio
- CASI N/A
- IMMX N/A
- Revenue Growth
- CASI N/A
- IMMX N/A
- 52 Week Low
- CASI $2.04
- IMMX $1.26
- 52 Week High
- CASI $7.67
- IMMX $3.35
- Technical
- Relative Strength Index (RSI)
- CASI 35.91
- IMMX 41.80
- Support Level
- CASI $2.15
- IMMX $1.51
- Resistance Level
- CASI $2.49
- IMMX $1.69
- Average True Range (ATR)
- CASI 0.15
- IMMX 0.14
- MACD
- CASI 0.00
- IMMX -0.00
- Stochastic Oscillator
- CASI 35.42
- IMMX 34.01
About CASI CASI Pharmaceuticals Inc.
CASI Pharmaceuticals Inc is a biopharmaceutical company that focuses on commercializing therapeutics and pharmaceutical products. The products include injections for patients who are suffering from leukemias and lymphomas. The EVOMELA injection is used as a conditioning treatment before autologous stem cell transplant for patients with multiple myeloma. The company products include CID-103, CNCT19, EVOMELA, MARQIBO, ZEVALIN, ENMD-2076 and others. The majority of the revenue is generated from the product sales of EVOMELA.
About IMMX Immix Biopharma Inc.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.